Homology Medicines Inc (NASDAQ:FIXX) CFO W Bradford Smith sold 6,000 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $16.00, for a total transaction of $96,000.00. Following the sale, the chief financial officer now directly owns 6,000 shares of the company’s stock, valued at $96,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
W Bradford Smith also recently made the following trade(s):
- On Monday, December 2nd, W Bradford Smith sold 6,000 shares of Homology Medicines stock. The stock was sold at an average price of $16.21, for a total transaction of $97,260.00.
- On Tuesday, October 1st, W Bradford Smith sold 6,000 shares of Homology Medicines stock. The stock was sold at an average price of $17.39, for a total transaction of $104,340.00.
Shares of NASDAQ FIXX traded up $1.18 during midday trading on Tuesday, reaching $18.32. The stock had a trading volume of 667,880 shares, compared to its average volume of 242,386. The company has a market capitalization of $704.55 million, a price-to-earnings ratio of -9.16 and a beta of 0.14. Homology Medicines Inc has a 12-month low of $11.05 and a 12-month high of $31.80. The stock has a 50-day moving average of $13.63 and a 200-day moving average of $17.60.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Aperio Group LLC bought a new position in Homology Medicines in the 2nd quarter worth $34,000. Bank of Montreal Can purchased a new stake in Homology Medicines in the 2nd quarter worth $40,000. Cubist Systematic Strategies LLC purchased a new stake in Homology Medicines in the 2nd quarter worth $42,000. Marshall Wace LLP bought a new stake in Homology Medicines during the first quarter valued at about $74,000. Finally, Royal Bank of Canada raised its holdings in Homology Medicines by 300.0% during the second quarter. Royal Bank of Canada now owns 4,000 shares of the company’s stock valued at $78,000 after acquiring an additional 3,000 shares during the period. Institutional investors own 71.06% of the company’s stock.
FIXX has been the subject of a number of recent research reports. Zacks Investment Research downgraded shares of Homology Medicines from a “hold” rating to a “sell” rating in a research report on Friday, November 15th. Robert W. Baird started coverage on Homology Medicines in a research report on Monday, September 9th. They issued an “outperform” rating and a $30.00 price target for the company. HC Wainwright set a $36.00 price objective on Homology Medicines and gave the stock a “buy” rating in a research note on Tuesday, September 24th. FIX started coverage on Homology Medicines in a research report on Thursday, October 31st. They set a “market perform” rating on the stock. Finally, ValuEngine downgraded Homology Medicines from a “buy” rating to a “hold” rating in a research note on Monday, November 25th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. Homology Medicines has a consensus rating of “Hold” and a consensus price target of $31.40.
Homology Medicines Company Profile
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Featured Article: Insider Trading – What You Need to Know
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.